

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

“STATE KEY LABORATORY FOR NOVEL PHARMACEUTICAL PREPARATIONS AND EXCIPIENTS” RATED AS EXCELLENT CLASS OF STATE KEY LABORATORY

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the State Key Laboratory for Novel Pharmaceutical Preparations and Excipients (the “**Laboratory**”) of the Group is rated excellent in the assessment of state key laboratories undertaken by the Ministry of Science and Technology of the People’s Republic of China (the “**Ministry of Science and Technology**”). This performance assessment undertaken by the Ministry of Science and Technology covers a five-year period of establishment and operation for 99 corporate state key laboratories which have passed the acceptance evaluation. The Laboratory is rated excellent and is the only state key laboratory in Hebei Province with excellent rating.

The Laboratory received the approval for establishment on 17 December 2010 and passed the acceptance evaluation on 19 January 2015 from the Ministry of Science and Technology. The Laboratory’s research and development mainly focus on four directions, namely targeted drug delivery technology, oral sustained-release drug delivery technology, biological macromolecule delivery technology and novel pharmaceutical excipients.

During the assessment period, the Laboratory has undertaken 25 national technology projects and 21 provincial technology projects; launched a number of preparation products (including Pegylated Recombinant Human Granulocyte Colony Stimulating Factor for Injection (Jinyouli), Butylphthalide for Injection (NBP), Doxorubicin Liposome for Injection (Duomeisu) and Paclitaxel for Injection (albumin-bound) (Keaili)) and three novel excipients (namely Hydroxypropyl- β -cyclodextrin, Cellulose Acetate and Phosphatidylethanolamine Pegol); obtained clinical approval and commenced clinical studies for a number of preparation products (including Amphotericin B Cholesteryl Sulfate Complex, Vinorelbine Liposome Formulation and Alprostadil Liposome Formulation) and excipients (including Cholesteryl Sulfate and Sulfobutyl Ether- β -cyclodextrin); commenced clinical studies for Mitoxantrone Liposome Formulation, Irinotecan Liposome Formulation, Butylphthalide Soft Capsules and Levamlodipine Maleate tablets in the United States; obtained orphan drug designation for Mitoxantrone Liposome Formulation, Antibody-drug Conjugate (ADC) Drug and Butylphthalide Soft Capsules; and entered into agreements of intellectual property rights licensing and commercial cooperation for preparation products with overseas companies.

Since its establishment, the Laboratory has obtained 81 domestic patents for inventions and submitted 21 PCT International applications, with patent rights obtained in a total of 64 countries. It has also received two Golden Awards for Outstanding Chinese Patented Invention, one State Technological Invention Award (Second Class), two State Science and Technology Progress Awards (Second Class) and four Hebei Province Science and Technology Progress Awards (First Class).

Looking forward, the Group will continue to leverage its technical advantages in this area and build the Laboratory into a leading corporate state key laboratory in China with international influence.

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 23 July 2018

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. WANG Jinxu, Mr. LU Hua, Mr. LI Chunlei, Mr. ZHANG Cuilong and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.